United States: FDA's Off-Label Hearing Set For The Day After The 2016 Election

Last Updated: September 9 2016
Article by Michael A. Walsh

On September 1, 2016 the Food and Drug Administration (FDA) issued its Notice of Public Hearing on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products (FDA's Off-Label Hearing). The FDA's Off-Label Hearing is scheduled for November 9-10, 2016, the Wednesday and Thursday immediately following the 2016 national election.

The FDA's Off-Label Hearing will begin the agency's Judgment of Solomon to decide where to draw the line between purported off-label promotion and the dissemination of truthful scientific and medical information. Off-label use is legal and is often recognized by the medical community and the FDA as the "standard of care." Yet data studying 725 million prescriptions showed that 20 percent were off-label and of those, 70 percent or over 100 million prescriptions were based on no science or weak science.1 On the other hand, the "promotion" of a product for an indication, dose or duration not in the FDA approved labeling is a "prohibited act" under the federal Food Drug and Cosmetic Act (FDCA) and is subject to civil and criminal enforcement.

This hearing is not the first FDA attempt at balancing the government's power to restrict speech by characterizing the dissemination of information by manufacturers as "promotion" or "promotional labeling." In 1996 and again in 2009, the FDA addressed manufacturer dissemination of information on the internet as its then "front burner" "high priority" issue and conducted multiple two day hearings, ultimately resulting in social media guidance being issued in 2014. Then, as now, Congress had left for the FDA the difficult task of navigating between allowing manufacturers to disseminate truthful scientific information and "promotional conduct.

Congress has provided little guidance to assist the FDA in threading the needle on regulating what a manufacturer can say about its products with the constraints of Due Process and the First Amendment. For the better part of the past decade, the FDA has been publically suggesting it will formulate a new set of rules balancing Due Process and the First Amendment. Earlier this year the FDA stated it would "[r]e-evaluate our regulation of drug advertising and promotion in light of current jurisprudence around the 1st Amendment" and placed the issue among its "Front Burner Priorities". The Off-Label Promotion Hearing is the FDA's important next step in the reevaluation process.

Most commentators agree that the 2016 election will have a significant impact on federal regulatory enforcement priorities and the FDA's Off-Label Promotion Hearing attendees will have little time to ponder the significance of the election results on the eight questions the FDA poses. The issues the FDA is seeking comment on include:

  1. What benefit is there to increased communications and how should it be done and monitored?
  2. What can be done to encourage supplemental applications for approval of the off-label or new use?
  3. What factors should manufacturers consider when disseminating off-label/new use information on the internet?
  4. What scientific and medical standards should apply to the information disseminated?
  5. How should the FDA assess "truthful and non-misleading" and are disclosures appropriate?
  6. What information from unpublished clinical studies should be made available?
  7. How should the FDA monitor the dissemination of new use information?
  8. What additional rules changes should the FDA consider?

For over 50 years, the FDA has justified constraining the free flow of product information by citing horrific instances from the past and the conduct of crooks, thieves and scoundrels who put harmful products in the marketplace with dreadful results. Nonetheless, constitutional considerations were given "back-burner" status and court challenges to the FDA's regime of enforcement have emerged only in fits and starts. The FDA's regulatory enforcement of off-label promotion began taking on water in earnest in 1998 in Washington Legal v Friedman. The Constitutional challenges to the scope of FDA oversight suffered another hit to the stern in 2002 in Thompson v Western States. But the early years of the century were a feeding frenzy for the FDA racking up billions of dollars in financial extractions from industry. Due Process and First Amendment defenses were no less potent then than they are today but manufacturers were rendered dumb in light of the ferocious threats of criminal and civil penalties that the government wielded. It wasn't until the State of Vermont went a step too far in Sorrell v IMS and the FDA started frying smaller fish that unexpected outcomes in seemingly insignificant cases moved the pendulum decidedly in favor of rejecting the approach the government had taken for decades.

The iceberg that hastened the sinking of the FDA's regulatory regime hit in 2012 in the landmark Second Circuit decision in US v. Caronia. Yet, despite that loss, the FDA continued rearranging the deck chairs until 2015 when the disastrous twins of Amarin and Pacira confirmed that the government is long overdue to revamp its regime governing the regulation of purported off-label communications. What Caronia, Amarin and Pacira now demonstrate is that the government's approach and severely punishing the free flow of truthful scientific and medical information suffers serious constitutional infirmities.

Beyond the constitutional issues, there is a moral imperative to provide more – not – less truthful scientific and medical information. The heart of the debate is the fact that no one has ever died or been injured because they had too much truthful scientific or medical information. But the opposite is certainly not true, and no one has been saved or cured by false or unreliable information.

This long overdue two-day Public Hearing will begin the contentious and challenging task of navigating Due Process and the First Amendment while placing significant restrictions on the free flow of information. After decades of denying the Constitution applies in the regulation, the FDA will need to listen closely.

History will likely forget that the FDA waited decades until the day after what is expected to be one of US history's most contentious elections, an election that will shape the Supreme Court for generations. What history may not forget or excuse is the continuance of a regulatory regime that throws the baby out with the bath water and restricts the free flow of truthful scientific and medical information.


1 See David C. Radley, Susan N. Finkelstein & Randall S. Stafford, Off-label Prescribing Among Office-Based Physicians, 166 Arch Intern Med 1021 (2006).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Michael A. Walsh
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions